← board
XTXXF
distress 0/10 · well-funded / low risk$0.010%today-99% from 52w high
Revenue
pre-revenue
Liquidity
$1M
Runway
—
Shares 1y
-15%
Price & events
-30.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
-30.0%
3M
-30.0%
6M
-81.5%
1Y
-99.6%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $391.79K
- Enterprise Value
- $3.08M
- Volume
- 0
- 52 Week Range
- $0.01 – $0.51
- Total Shares
- 55.97M
- Float Shares
- 5.53M
- % Held by Insiders
- 1.27%
- % Held by Institutions
- 0.00%
- Beta
- -0.50
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-07-23Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 55,970,547 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.